Stephen Mahoney's most recent trade in Viridian Therapeutics Inc was a trade of 440,565 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | Stephen Mahoney | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 440,565 | 440,565 | - | - | Stock Option (Right to Buy) | |
| Viridian Therapeutics Inc | Stephen Mahoney | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 73,428 | 73,428 | - | - | Restricted Stock Units | |
| Viridian Therapeutics Inc | Stephen Mahoney | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 23.33 per share. | 27 Sep 2024 | 21,400 | 21,400 (0%) | 0% | 23.3 | 499,262 | Common Stock |